The looming question: who pays?


An Australian S8 first once again raises the question of MBS numbers for pharmacists, writes Angelo Pricolo Patients are the real winners as Victorian pharmacists will become the first in Australia to administer Long Acting Injectable Buprenorphine (LAIB). Importantly this will be the first non-vaccine product that pharmacists will administer in Australia and significant also

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Clinical tips: substance abuse
Next How will you handle temporary closure?